Cyclica and AUM Biosciences Collaborate to Develop Novel Cancer Therapies Under Project Nexus

 Cyclica and AUM Biosciences Collaborate to Develop Novel Cancer Therapies Under Project Nexus

Cyclica and AUM Biosciences Collaborate to Develop Novel Cancer Therapies Under Project Nexus

Shots:

  • Cyclica to receive up front, milestones upon completion of specific stages for Project Nexus. AUM to get right to develop & commercialize therapies resulting from Project Nexus
  • The collaboration leverages AUM’s drug development expertise including its biomarker-driven approach with Cyclica’s AI-augmented and structure-based platform, Ligand Design and Ligand Express
  • The companies will design molecules with greater precision and speed, minimizing unwanted off-target effects while providing an understanding of their activity via systems biology and structural pharmacogenomics, addressing the unmet medical needs of patients in Asia

Click here ­to­ read full press release/ article | Ref: Business wire | Image: AUM Bioscience

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post